Global: Glaxo to launch final-stage malaria vaccine trial

GlaxoSmithKline Plc is about to start final-stage clinical trials of the world's most advanced malaria vaccine, which could reach the market within three years, the British-based drugmaker said on Friday. If successful, Glaxo believes its Mosquirix vaccine has the potential to save hundreds of thousands of deaths and prevent tens of millions of cases of malaria in Africa.